A powered wound dressing designed to target biofilm and drug-resistant pathogens.

Gen 2 dressing (planned commercial candidate); clinical results are from Gen 1.
Pavaka Wound Care is a medical device company pursuing FDA clearance for an investigational dressing that generates a low-level electric field at the wound surface. The Gen 1 dressing was studied in a 112-patient randomized trial funded by the U.S. Department of Defense (NCT04794621), and Pavaka’s technology is protected by an issued U.S. patent and an allowed patent application, exclusively licensed from The Ohio State University.
It is designed to help clinicians address biofilm infection, one of the most persistent barriers to wound closure.
The dressing is investigational. It has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.

Exclusive Ohio State license

112-patient DoD-funded randomized study

6 peer-reviewed studies

Gen 2 built for high-speed production
Regulatory path: 510(k) for the three-volt Gen 2 configuration;
De Novo for the six-volt configuration.
Both investigational.
Biofilm: a major barrier to wound closure
Most chronic wounds contain biofilm. In a meta-analysis of published studies, biofilm was present in 78.2% of chronic wounds (Malone et al., J Wound Care, 2017). Biofilm shields bacteria from antibiotics and the immune system.
Antimicrobial resistance is rising worldwide: the World Health Organization reports that about 1 in 6 laboratory-confirmed bacterial infections is resistant to antibiotic treatment (WHO GLASS report, 2025). Clinicians need new, non-antibiotic approaches.
Our first focus is orthopedic and foot-and-ankle surgery, where surgical-site infection is a costly complication.
We Have Reached a Crisis Point
No innovative therapeutic strategies exist to combat multidrug-resistant organisms and biofilm infection by a broad range of microbes in wounds and burns. The multidrug resistance crisis continues to worsen for many reasons including overuse and incorrect use of antibiotics. The crisis has reached a critical point where antibiotics are no longer effective against modest infections and often result in expensive complex care including hospitalization, treatment failure and the persistence of drug-resistant pathogens.
Video Source: FDA, May 2024
Pavaka’s investigational dressing generates a low-level electric field at the wound surface and is being developed to address biofilm and drug-resistant infection in wounds.
What wound care clinicians told us
For biofilm, there’s no real prevention, only treatment. When patients come in after months of antibiotics but no progress, it’s because no one addressed the biofilm.
— Director, hospital-based advanced wound care center
Silver dressings have some antimicrobial activity; some use topicals. I’m not aware of a product that claims biofilm prevention/disruption as its central mechanism.
— Vascular surgeon, academic medical center
Feedback gathered during 2025 customer discovery interviews. Shared to illustrate clinical need; not an endorsement or a claim of safety or effectiveness.
An electric field, delivered by a dressing

The Pavaka dressing is a flexible, single-use wound dressing with a printed electrode pattern. It generates a low-level electric field at the wound surface. The goal is to disrupt biofilm without relying on antibiotics. Unlike passive dressings, the Pavaka dressing is actively powered by an onboard battery, so the field it generates can be set by design.
Studied in a randomized trial funded by the Department of Defense

In a 112-patient randomized study funded by the U.S. Department of Defense (NCT04794621), biofilm was measured during the first three weeks, when patients received Pavaka’s Gen 1 dressing. Biofilm abundance fell 40% from the first visit to week 3 in patients on the Gen 1 dressing plus standard care, while the standard-care group did not improve. Full results are being prepared for peer-reviewed publication.
Six peer-reviewed studies, plus a 2026 review article, from Ohio State, Indiana University and collaborators describe the platform’s bench, preclinical, veterinary and early clinical research. Results are from research studies and are not claims of safety or effectiveness.
Where our programs stand

As of November 2026. Investigational and research programs; none is cleared or approved by the U.S. FDA or available for sale.
Electroceutical wound dressing
Lead program · infected surgical and trauma wounds
Stage 4 of 6: Clinical research
Early clinical studies completed with the Gen 1 dressing; six-volt Gen 2 design for line manufacturing completed and compared with Gen 1 in laboratory testing.
Surgical incision site dressing
Research program · surgical incision sites
Stage 1 of 6: Research & concept
Early research and development; no clinical data.
Layered dressing
Research program · collagen, fiber, foam and negative pressure wound therapy
Stage 1 of 6: Research & concept
Early research into pairing the electroceutical layer with dressings clinicians already use; no clinical data.
Fungal infections device
Research program · fungal wound infections
Stage 1 of 6: Research & concept
Early research and development; no clinical data.
Qualitative development view only — not a clearance forecast. Gen 2 has not been studied in patients.
University science, built into a medical device company
Pavaka Wound Care was co-founded in Columbus, Ohio, by Brent Toto and Frank Fischer. Our focus is translating an academic electroceutical platform into disciplined medical device development.
Our team includes a CTO who helped bring 50+ products to market at Cook Medical, the randomized study’s principal investigator as CSO, and a retired Army infectious disease physician as CMO.
Support and recognition: MTEC preclinical and clinical awards · Ohio Third Frontier TVSF award · Rev1 Ventures Concept award
